Skip to content
Screener

Opus Genetics IRD Price / sales

Price / sales at other companies

AbbVie logo
AbbVieABBV
6.9×+1.3×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
8.8×-6.6×
Regenxbio logo
RegenxbioRGNX
3.5×+0.8×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
5.4×-6,497×
Opko Health logo
Opko HealthOPK
1.9×+0.4×
uniQure logo
uniQureQURE
169.6×+115×

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$304.5M+381%
Enterprise value$245.74M+672%

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

market cap/total revenue=27×

Based on the most recent quarter.

The source filing: Opus Genetics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034084

FAQ

What is Opus Genetics's price / sales?
Opus Genetics (IRD) reported price / sales of 27× in Q1 2026.
How has Opus Genetics's price / sales changed year-over-year?
Opus Genetics's price / sales increased by 735.4% year-over-year, from 3.2× to 27×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Ask your AI about Opus Genetics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude